Quick Answer
Climb Bio, Inc. reported Net Income Loss of -$59.85 million for the year ending 2025.
- Climb Bio, Inc. showed an increase of +19.0% in Net Income Loss from 2024 to 2025.
- This data is from Climb Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$1.63 million | Q3 2020: -$2.26 million | Q1 2021: -$18.60 million | Q2 2021: -$8.72 million | Q3 2021: -$9.62 million | Q1 2022: -$13.20 million | Q2 2022: -$14.60 million | Q3 2022: -$9.68 million | Q1 2023: -$22.29 million | Q2 2023: -$5.22 million | Q3 2023: -$3.97 million | Q1 2024: -$1.70 million | Q2 2024: -$54.89 million | Q3 2024: -$8.90 million | Q1 2025: -$20.78 million | Q2 2025: -$8.67 million | Q3 2025: -$12.89 million.
- Over the full 6 years of available data (2020 to 2025), Climb Bio, Inc.'s Net Income Loss has declined by 189.6%.
- Historical annual values: Fiscal year 2025: -$59.85 million | Fiscal year 2024: -$73.90 million | Fiscal year 2023: -$35.12 million | Fiscal year 2022: -$45.24 million | Fiscal year 2021: -$47.48 million | Fiscal year 2020: -$20.67 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: